Durvalumab Monotherapy and Combination Therapy in PD-L1–Low/Negative HNSCC

This phase 2 randomized clinical trial compare the efficacy and toxicity profiles of durvalumab monotherapy and tremelimumab monotherapy against a combination of both in patients with recurrent or metastatic head and neck squamous cell carcinoma with low or no expression of programmed death ligand 1.

https://ift.tt/2Px4C2u